They are administered long term for the treatment of gastric ulcer disease, gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and related conditions1. H2R antagonists decrease the volume and concentration of gastric acid produced by gastric parietal cells2. The gene discussed is HRH2; the disease is gastroesophageal reflux disease.